I-Mab Biopharma of Shanghai out-licensed global rights (ex-China) for bispecific antibodies to ABL Bio of South Korea in an agreement worth about $100 million. Neither the target nor the proposed indications of the molecules were disclosed. I-Mab is focused on biologics for immuno-oncology and immuno-inflammation needs. ABL will make a $2.5 million payment to I-Mab up front and agreed to pay around $100 million in milestones, plus royalties. The two companies also agreed to co-develop three additional BsAbs globally as part of the partnership.
Source: China Biotoday
